NASDAQ:IDXX - IDEXX Laboratories Stock Price, Price Target & More

IDEXX Laboratories trades on the NASDAQ under the ticker symbol "IDXX."

IDEXX Laboratories declared that its board has authorized a stock buyback plan on Sunday, June 4th 2017, which authorizes the company to buyback 3,000,000 shares, according to EventVestor. This buyback authorization authorizes the company to purchase shares of its stock through open market purchases. Shares buyback plans are typically a sign that the company's board believes its stock is undervalued.

IDEXX Laboratories, Inc. (NASDAQ:IDXX) issued its quarterly earnings results on Friday, May, 4th. The company reported $1.01 EPS for the quarter, topping the Thomson Reuters' consensus estimate of $0.92 by $0.09. The company earned $537.60 million during the quarter, compared to the consensus estimate of $525.14 million. IDEXX Laboratories had a negative return on equity of 530.24% and a net margin of 13.87%. The business's revenue was up 16.4% compared to the same quarter last year. During the same period last year, the company posted $0.77 EPS. View IDEXX Laboratories' Earnings History.

IDEXX Laboratories is scheduled to release their next quarterly earnings announcement on Thursday, August, 2nd 2018. View Earnings Estimates for IDEXX Laboratories.

IDEXX Laboratories updated its FY18 earnings guidance on Friday, May, 4th. The company provided earnings per share (EPS) guidance of $4.06-4.20 for the period, compared to the Thomson Reuters consensus EPS estimate of $4.11. The company issued revenue guidance of +12-14% to ~$2.205-2.245 billion, compared to the consensus revenue estimate of $2.22 billion.

7 Wall Street analysts have issued 12 month price objectives for IDEXX Laboratories' shares. Their predictions range from $200.00 to $231.00. On average, they expect IDEXX Laboratories' share price to reach $217.00 in the next twelve months. View Analyst Ratings for IDEXX Laboratories.

Some companies that are related to IDEXX Laboratories include IPSEN S A/S (IPSEY), Neogen (NEOG), Immunomedics (IMMU), Myriad Genetics (MYGN), Quidel (QDEL), Intellia Therapeutics (NTLA), Meridian Bioscience (VIVO), Lantheus (LNTH), Oxford Immunotec Global (OXFD), Quotient (QTNT), Nymox Pharmaceutical (NYMX), Trinity Biotech (TRIB), Riot Blockchain (RIOT), Celldex Therapeutics (CLDX) and Vermillion (VRML).

Headlines about IDXX stock have been trending somewhat positive this week, according to Accern. The research group rates the sentiment of press coverage by monitoring more than 20 million blog and news sources. Accern ranks coverage of companies on a scale of negative one to one, with scores closest to one being the most favorable. IDEXX Laboratories earned a media sentiment score of 0.19 on Accern's scale. They also gave news articles about the company an impact score of 46.86 out of 100, meaning that recent press coverage is somewhat unlikely to have an effect on the stock's share price in the near term.

IDEXX Laboratories' stock is owned by many different of retail and institutional investors. Top institutional investors include BlackRock Inc. (7.61%), Bamco Inc. NY (5.15%), Blair William & Co. IL (1.87%), Neuberger Berman Group LLC (1.86%), Northern Trust Corp (1.16%) and Old Mutual Global Investors UK Ltd. (1.08%). Company insiders that own IDEXX Laboratories stock include Barry C Johnson, Brian P Mckeon, Bruce L Claflin, Daniel M Junius, Giovani Twigge, Jacqueline Studer, Jonathan W Ayers, Lawrence D Kingsley, Michael J Phd Williams, Rebecca M Henderson, Thomas Craig and William T End. View Institutional Ownership Trends for IDEXX Laboratories.

IDXX stock was sold by a variety of institutional investors in the last quarter, including BlackRock Inc., Bamco Inc. NY, Blair William & Co. IL, Millennium Management LLC, Federated Investors Inc. PA, Natixis, American Century Companies Inc. and Old Mutual Global Investors UK Ltd.. Company insiders that have sold IDEXX Laboratories company stock in the last year include Brian P Mckeon, Daniel M Junius, Giovani Twigge, Jacqueline Studer, Jonathan W Ayers, Rebecca M Henderson and William T End. View Insider Buying and Selling for IDEXX Laboratories.

IDXX stock was bought by a variety of institutional investors in the last quarter, including Lord Abbett & CO. LLC, AGF Investments Inc., Prudential Financial Inc., OppenheimerFunds Inc., Westfield Capital Management Co. LP, Wells Fargo & Company MN, Select Equity Group L.P. and Chicago Capital LLC. Company insiders that have bought IDEXX Laboratories stock in the last two years include Bruce L Claflin and Lawrence D Kingsley. View Insider Buying and Selling for IDEXX Laboratories.

Shares of IDXX can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

One share of IDXX stock can currently be purchased for approximately $221.91.

IDEXX Laboratories has a market capitalization of $19.58 billion and generates $1.97 billion in revenue each year. The company earns $263.14 million in net income (profit) each year or $3.28 on an earnings per share basis. IDEXX Laboratories employs 7,600 workers across the globe.

IDEXX Laboratories' mailing address is ONE IDEXX DRIVE, WESTBROOK ME, 04092. The company can be reached via phone at 207-556-0300 or via email at [email protected]